Market closed
Unity Biotechnology Inc./$UBX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Ticker
$UBX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
16
Website
UBX Metrics
BasicAdvanced
$16M
-
-$1.54
1.02
-
Price and volume
Market cap
$16M
Beta
1.02
52-week high
$1.98
52-week low
$0.85
Average daily volume
198K
Financial strength
Current ratio
2.621
Quick ratio
2.524
Long term debt to equity
303.496
Total debt to equity
362.473
Management effectiveness
Return on assets (TTM)
-34.43%
Return on equity (TTM)
-148.97%
Valuation
Price to book
2.47
Price to tangible book (TTM)
2.47
Price to free cash flow (TTM)
-0.768
Growth
Earnings per share change (TTM)
-42.75%
3-year earnings per share growth (CAGR)
-47.83%
UBX News
AllArticlesVideos
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
Benzinga·3 weeks ago
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
GlobeNewsWire·3 weeks ago
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Unity Biotechnology Inc. stock?
Unity Biotechnology Inc. (UBX) has a market cap of $16M as of April 17, 2025.
What is the P/E ratio for Unity Biotechnology Inc. stock?
The price to earnings (P/E) ratio for Unity Biotechnology Inc. (UBX) stock is 0 as of April 17, 2025.
Does Unity Biotechnology Inc. stock pay dividends?
No, Unity Biotechnology Inc. (UBX) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Unity Biotechnology Inc. dividend payment date?
Unity Biotechnology Inc. (UBX) stock does not pay dividends to its shareholders.
What is the beta indicator for Unity Biotechnology Inc.?
Unity Biotechnology Inc. (UBX) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.